Your browser doesn't support javascript.
loading
MLL-AF4 cooperates with PAF1 and FACT to drive high-density enhancer interactions in leukemia.
Crump, Nicholas T; Smith, Alastair L; Godfrey, Laura; Dopico-Fernandez, Ana M; Denny, Nicholas; Harman, Joe R; Hamley, Joseph C; Jackson, Nicole E; Chahrour, Catherine; Riva, Simone; Rice, Siobhan; Kim, Jaehoon; Basrur, Venkatesha; Fermin, Damian; Elenitoba-Johnson, Kojo; Roeder, Robert G; Allis, C David; Roberts, Irene; Roy, Anindita; Geng, Huimin; Davies, James O J; Milne, Thomas A.
  • Crump NT; MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, OX3 9DS, UK. n.crump@imperial.ac.uk.
  • Smith AL; Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, W12 0NN, UK. n.crump@imperial.ac.uk.
  • Godfrey L; MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, OX3 9DS, UK.
  • Dopico-Fernandez AM; MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, OX3 9DS, UK.
  • Denny N; MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, OX3 9DS, UK.
  • Harman JR; MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, OX3 9DS, UK.
  • Hamley JC; MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, OX3 9DS, UK.
  • Jackson NE; MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, OX3 9DS, UK.
  • Chahrour C; MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, OX3 9DS, UK.
  • Riva S; MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, OX3 9DS, UK.
  • Rice S; MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, OX3 9DS, UK.
  • Kim J; MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, OX3 9DS, UK.
  • Basrur V; Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, 34141, South Korea.
  • Fermin D; Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA.
  • Elenitoba-Johnson K; Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA.
  • Roeder RG; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Allis CD; Laboratory of Biochemistry and Molecular Biology, The Rockefeller University, New York, NY, 10065, USA.
  • Roberts I; Laboratory of Chromatin Biology and Epigenetics, The Rockefeller University, New York, NY, 10065, USA.
  • Roy A; MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, OX3 9DS, UK.
  • Geng H; Department of Paediatrics, University of Oxford, Oxford, OX3 9DU, UK.
  • Davies JOJ; MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, OX3 9DS, UK.
  • Milne TA; Department of Paediatrics, University of Oxford, Oxford, OX3 9DU, UK.
Nat Commun ; 14(1): 5208, 2023 08 25.
Article en En | MEDLINE | ID: mdl-37626123
ABSTRACT
Aberrant enhancer activation is a key mechanism driving oncogene expression in many cancers. While much is known about the regulation of larger chromosome domains in eukaryotes, the details of enhancer-promoter interactions remain poorly understood. Recent work suggests co-activators like BRD4 and Mediator have little impact on enhancer-promoter interactions. In leukemias controlled by the MLL-AF4 fusion protein, we use the ultra-high resolution technique Micro-Capture-C (MCC) to show that MLL-AF4 binding promotes broad, high-density regions of enhancer-promoter interactions at a subset of key targets. These enhancers are enriched for transcription elongation factors like PAF1C and FACT, and the loss of these factors abolishes enhancer-promoter contact. This work not only provides an additional model for how MLL-AF4 is able to drive high levels of transcription at key genes in leukemia but also suggests a more general model linking enhancer-promoter crosstalk and transcription elongation.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Proteínas Nucleares / Leucemia Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Proteínas Nucleares / Leucemia Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article